Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi’s Novel Antibiotic Fetroja Now Available in Japan
Shionogi launched its novel siderophore cephalosporin antibiotic Fetroja (cefiderocol) in Japan on December 20. Testing reagents to measure sensitivity to the drug will be rolled out on December 22, the company said. In Japan, Fetroja was approved on November 30…
To read the full story
Related Article
- Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
December 14, 2023
- Shionogi’s Cefiderocol Selected for Pilot-Based Revenue Assurance System
November 13, 2023
BUSINESS
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
- Pfizer’s Tukysa Makes Japan Debut for HER2-Positive Breast Cancer
April 22, 2026
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Samsca Generics Extend Label to ADPKD
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…